Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.2 USD | +4.76% | -4.35% | -67.33% |
Financials (USD)
Sales 2022 | 13.48 | Sales 2023 | 15.77 | Capitalization | 9.96M |
---|---|---|---|---|---|
Net income 2022 | -96M | Net income 2023 | -75M | EV / Sales 2022 | -836,796 x |
Net cash position 2022 | 63.29M | Net Debt 2023 | 15.36M | EV / Sales 2023 | 1,605,487 x |
P/E ratio 2022 |
-0.51
x | P/E ratio 2023 |
-0.13
x | Employees | 25 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.23% |
Latest transcript on Eiger BioPharmaceuticals, Inc.
1 day | +4.76% | ||
1 week | -4.35% | ||
Current month | +2.33% | ||
1 month | -17.60% | ||
3 months | -62.01% | ||
6 months | -77.78% | ||
Current year | -67.33% |
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
James Vollins
CMP | Compliance Officer | 55 | 23-04-12 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-07-17 | |
Thomas Dietz
CHM | Chairman | 60 | 16-03-21 |
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.00% | 17 M€ | +5.25% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 2.2 | +4.76% | 19,986 |
24-05-24 | 2.1 | -3.23% | 5,150 |
24-05-23 | 2.17 | +0.93% | 9,341 |
24-05-22 | 2.15 | -6.52% | 5,454 |
24-05-21 | 2.3 | +1.32% | 523 |
Delayed Quote OTC Markets, May 28, 2024 at 03:56 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-67.33% | 3.26M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.21% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- EIGR Stock